UK Government Letter of Guidance On Cannabis Based Products for Medicinal Use 31/10/18. Prior to legalization on 1st November 2018

http://www.england.nhs.uk/wp-content/uploads/2018/10/letter-guidance-on-cannabis-based-products-for-medicinal-use..pdf

CBD Talk Podcast: Chris Driessen

A fantastic podcast on the topic

DEA Green Lights Epidiolex as First Cannabis Derived Pharmaceutical

SOURCE: https://www.newcannabisventures.com/dea-green-lights-epidiolex-as-first-cannabis- September 27, 2018 at 9:22 am Breaking News by Alan Brochstein, CFA The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V status according to the Office of the Federal Register. The developer of the pharmaceutical, GW Pharma (NASDAQ:

Detailed analysis of selected pathological conditions and effects of cannabis and its derivatives with weaker clinical evidence and a strong theoretical basis favoring effectiveness. With reference to Parkinson’s disease.

A short quote from the .pdf (a link to the detailed analysis is at the end of this post). ” Parkinson’s disease This disease, whose symptoms especially include a decrease in the number of dopaminergic neurons in the basal ganglia (“BG”), is, due to its high prevalence (especially among older patients) and simultaneous existence of endocannabinoid receptors in the BG